MCID: SMT006
MIFTS: 55

Somatoform Disorder

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Somatoform Disorder

MalaCards integrated aliases for Somatoform Disorder:

Name: Somatoform Disorder 12 14 69
Physiological Malfunction Arising from Mental Factor 12
Psychophysiologic Disorders 69
Psychosomatic Disorder 12

Classifications:



Summaries for Somatoform Disorder

Disease Ontology : 12 A disease of mental health that involves physical symptoms suggesting a physical illness where the biological or medical cause of the symptoms is indeterminate.

MalaCards based summary : Somatoform Disorder, also known as physiological malfunction arising from mental factor, is related to chronic pain and post-traumatic stress disorder, and has symptoms including symptoms, neuromuscular manifestations and labored breathing. An important gene associated with Somatoform Disorder is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are Th17 cell differentiation and Neuroscience. The drugs Pregabalin and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include prostate, brain and cortex, and related phenotypes are homeostasis/metabolism and cardiovascular system

Related Diseases for Somatoform Disorder

Diseases related to Somatoform Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 120)
# Related Disease Score Top Affiliating Genes
1 chronic pain 30.5 COMT OPRM1
2 post-traumatic stress disorder 30.1 COMT FAAH IL1B
3 irritable bowel syndrome 29.9 TAC1 TPH1 TRPV1
4 paine syndrome 29.7 CABIN1 IL1B NGF SCN9A TAC1 TRPA1
5 complex regional pain syndrome 29.6 IL1B SCN9A TAC1
6 cystitis 29.5 NGF TAC1 TRPV1
7 interstitial cystitis 29.2 IL4 NGF TAC1 TRPV1
8 somatization disorder 11.9
9 hypochondriasis 11.4
10 conversion disorder 11.2
11 dissociative seizures 11.2
12 psychogenic movement 11.2
13 body dysmorphic disorder 11.2
14 anxiety 10.7
15 panic disorder 10.6
16 chronic follicular conjunctivitis 10.5 IL1A IL1B
17 diversion colitis 10.5 IL1B IL4
18 hyperlucent lung 10.5 IL2RA IL4
19 neonatal abstinence syndrome 10.4 COMT OPRM1
20 obsessive-compulsive disorder 10.4
21 hypersensitivity reaction disease 10.4 IL1B IL4 TRPV1
22 vulvar vestibulitis syndrome 10.4 IL1B IL1RN
23 immune system disease 10.4 IL1B IL4 TRPV1
24 gastric cancer, hereditary diffuse 10.4 IL1B IL1RN
25 childhood-onset schizophrenia 10.3 COMT TPH1
26 autoimmune encephalitis 10.3 FAAH TRPV1
27 tonsillitis 10.3 IL1A IL1B IL4
28 polysubstance abuse 10.3 COMT FAAH
29 congenital hypogammaglobulinemia 10.3 IL1A IL4
30 gingivitis 10.3 IL1A IL1B IL4
31 contact dermatitis 10.3 IL1A IL1B IL4
32 disease of mental health 10.3 COMT OPRM1 TRPV1
33 aphthous stomatitis 10.3 IL1B IL1RN IL4
34 schnitzler syndrome 10.3 IL1B IL1RN
35 tobacco addiction 10.3 COMT OPRM1 TPH1
36 meningococcemia 10.3 IL1A IL1B IL1RN
37 root resorption 10.3 IL1A IL1B IL1RN
38 periodontitis 10.3 IL1A IL1B IL4
39 paroxysmal extreme pain disorder 10.3 SCN9A TRPV1
40 leishmaniasis 10.3 IL1A IL1B IL4
41 silicosis 10.3 IL1A IL1B IL1RN
42 alexithymia 10.3
43 osteomyelitis 10.3 IL1A IL1B IL1RN
44 interstitial lung disease 10.3 IL1A IL1B IL4
45 pertussis 10.3 IL1A IL1B OPRM1
46 episodic pain syndrome, familial, 1 10.3
47 lesion of sciatic nerve 10.2 NGF TRPV1
48 cerebral artery occlusion 10.2 IL1B IL1RN
49 brucellosis 10.2 IL1RN IL2RA IL4
50 juvenile rheumatoid arthritis 10.2 IL1B IL1RN IL2RA

Graphical network of the top 20 diseases related to Somatoform Disorder:



Diseases related to Somatoform Disorder

Symptoms & Phenotypes for Somatoform Disorder

UMLS symptoms related to Somatoform Disorder:


symptoms, neuromuscular manifestations, labored breathing, neurobehavioral manifestations, multiple somatic complaints, vertigo, seizures, reflex, abnormal, pain, meningism, headache, dyspnea

MGI Mouse Phenotypes related to Somatoform Disorder:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.07 IL4 COMT NGF FAAH OPRM1 GCH1
2 cardiovascular system MP:0005385 9.97 COMT NGF GCH1 TAC1 IL1A TPH1
3 immune system MP:0005387 9.9 IL4 CABIN1 COMT OPRM1 SCN9A IL1A
4 integument MP:0010771 9.73 IL4 NGF FAAH OPRM1 SCN9A IL1A
5 nervous system MP:0003631 9.32 TRPV1 IL4 COMT NGF FAAH OPRM1

Drugs & Therapeutics for Somatoform Disorder

Drugs for Somatoform Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 199)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3 148553-50-8 5486971
2
Triamcinolone Approved, Vet_approved Phase 4,Phase 3 124-94-7 31307
3
Citalopram Approved Phase 4,Phase 3 59729-33-8 2771
4 Piracetam Approved, Investigational Phase 4 7491-74-9
5
Fluoxetine Approved, Vet_approved Phase 4,Phase 1,Phase 2 54910-89-3 3386
6
Acetaminophen Approved Phase 4 103-90-2 1983
7
Cycloserine Approved Phase 4,Early Phase 1 68-41-7 6234 401
8
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
9
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
10
Lidocaine Approved, Vet_approved Phase 4,Phase 2 137-58-6 3676
11
Sertraline Approved Phase 4 79617-96-2 68617
12
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Early Phase 1 51-84-3 187
13
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
14
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
15
Flunarizine Approved Phase 4 52468-60-7 941361
16
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
17
Norepinephrine Approved Phase 4 51-41-2 439260
18
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
19 Etiracetam Investigational Phase 4 33996-58-6
20 Mosapride Investigational Phase 4 112885-41-3
21 Anticoagulants Phase 4,Phase 2
22 Pentosan Sulfuric Polyester Phase 4
23 Anticonvulsants Phase 4,Phase 3,Phase 2
24 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Antidepressive Agents, Second-Generation Phase 4,Phase 3,Phase 1,Phase 2
26 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
28 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
29
Serotonin Phase 4,Phase 3,Phase 1,Phase 2 50-67-9 5202
30 Serotonin Agents Phase 4,Phase 3,Phase 1,Phase 2
31 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
32 Anesthetics Phase 4,Phase 3,Phase 2
33 Anesthetics, Local Phase 4,Phase 3,Phase 2
34 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
35 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
37 Anti-Anxiety Agents Phase 4,Phase 3
38 Antiparkinson Agents Phase 4,Phase 3
39 calcium channel blockers Phase 4,Phase 3
40 Calcium, Dietary Phase 4,Phase 3,Phase 2
41 Tranquilizing Agents Phase 4,Phase 3
42 Cholinergic Agents Phase 4,Phase 3,Phase 2,Early Phase 1
43 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
44 triamcinolone acetonide Phase 4,Phase 3
45 Triamcinolone diacetate Phase 4,Phase 3
46 Triamcinolone hexacetonide Phase 4,Phase 3
47 Autonomic Agents Phase 4,Phase 3
48 Cholinergic Antagonists Phase 4,Phase 3
49 Muscarinic Antagonists Phase 4,Phase 3
50 Parasympatholytics Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 236)

# Name Status NCT ID Phase Drugs
1 Efficacy Study of Pentosan Polysulfate Sodium,Hydrodistension and Combination Therapy for Bladder Pain Syndrome Unknown status NCT01895153 Phase 4
2 Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder Completed NCT00265109 Phase 4 Levetiracetam
3 Fluoxetine in Pediatric Body Dysmorphic Disorder Completed NCT00245635 Phase 4 Fluoxetine;Placebo
4 Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain Completed NCT02385266 Phase 4 D-Cycloserine;Placebo (for D-cycloserine)
5 Lansoprazole Versus Mosapride for Functional Dyspepsia Completed NCT00663897 Phase 4 lansoprazole;mosapride
6 Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy. Completed NCT01250184 Phase 4 Lidocaine injection
7 Treatment Trial for Psychogenic Nonepileptic Seizures Completed NCT00835627 Phase 4 sertraline
8 Treatments for Psychogenic Nonepileptic Seizures (NES) Completed NCT00159965 Phase 4 sertraline;placebo
9 GRASSP: Gralise® for Spine Surgery Pain Recruiting NCT01764464 Phase 4 Gralise®;Placebo
10 Neurologic Signatures of Chronic Pain Disorders Recruiting NCT02747940 Phase 4 flunarizine and/or pregabalin
11 CBT as an Adjunct to SRIs in the Treatment of BDD Terminated NCT00211809 Phase 4 Venlafaxine
12 Botox as a Treatment for Chronic Male Pelvic Pain Syndrome Terminated NCT00194623 Phase 4 Botulinum Toxin A (Botox)
13 Using Saline for Myofascial Pain Syndromes (USAMPS) Terminated NCT02120261 Phase 4
14 Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective Study Terminated NCT01879930 Phase 4 doxycycline;placebo
15 Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study Terminated NCT01280747 Phase 4
16 Sinusitis and Facial Pain Disorders Anti-Depression Trial Terminated NCT00754793 Phase 4 escitalopram;placebo
17 Comparative Study of Epigastric Pain Syndrome and Postprandial Distress Syndrome Withdrawn NCT00673972 Phase 4
18 RCT :Thoracic Sympathetic Block for the Treatment of Complex Regional Pain Syndrome I of the Upper Limb Unknown status NCT01612364 Phase 3
19 Analysis of Photoplethysmographic Signal in Lumbar Sympathetic Block Unknown status NCT01134289 Phase 3
20 Intravenous Immunoglobulins in Complex-regional Pain Syndrome Unknown status NCT00949065 Phase 3
21 Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Unknown status NCT00371033 Phase 3 Pregabalin;Placebo
22 DEPENAS: A Psychosocial Intervention for Patients With Medically Unexplained Symptoms Completed NCT00130988 Phase 3
23 Treatment of Medically Unexplained Physical Ailments (Somatization Disorder) Completed NCT00050583 Phase 3
24 Comparing Cognitive Therapy and Exposure Therapy in Individuals With Hypochondriasis Completed NCT01119469 Phase 3
25 Integrated Treatment Program for Hypochondriasis in Primary Care Settings Completed NCT00368212 Phase 3
26 Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder Completed NCT00149799 Phase 3 Escitalopram;Placebo
27 Cytokine Inhibition in Chronic Fatigue Syndrome Patients Completed NCT02108210 Phase 2, Phase 3 Anakinra;Placebo
28 Treatment of Patients With Longstanding Unexplained Health Complaints Completed NCT00132197 Phase 2, Phase 3
29 Prevalence of Salivary Hypofunction in Patients With Globus Pharyngeus Completed NCT00381771 Phase 2, Phase 3
30 Diacutaneous Fibrolysis and Patellofemoral Pain Syndrome Completed NCT02379364 Phase 3
31 Biofeedback-Based Cognitive Behavioral Treatment for Temporomandibular Disorders Completed NCT00769561 Phase 2, Phase 3
32 Pain Exposure Physical Therapy (PEPT) Versus CBO in Patients With Complex Regional Pain Syndrome Type I (CRPS-1) Completed NCT00817128 Phase 2, Phase 3
33 A Study of the Combination of Electrical Stimulation and Dysport® in Myofascial Pain Syndrome. Completed NCT00246142 Phase 3 Botulinum type A toxin (Dysport)
34 A Study of the Effect of Lenalidamide on Complex Regional Pain Syndrome Type 1 Completed NCT00166452 Phase 3 Lenalidamide
35 Efficacy Study of a Standardized Pollen Extract Preparation (Cernilton) to Treat Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome (CP-CPPS) Completed NCT00919893 Phase 3 Cernilton;Placebo
36 A Confirmatory Study of Fentanyl in Participants With Post-herpetic Neuralgia, Complex Regional Pain Syndrome or Postoperative Pain Syndrome Completed NCT01008553 Phase 3 Fentanyl;Placebo
37 Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome Recruiting NCT03184545 Phase 3
38 Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome Recruiting NCT02858453 Phase 3 AQX-1125 100 mg;AQX-1125 200 mg;Placebo
39 Role of Vitamin C at 6 Months on Incidence of Complex Regional Pain Syndrome Type I in Upper Limb Surgery Recruiting NCT02390505 Phase 3 Vitamin C;Placebo
40 Treatment of Globus Sensations With Psychotherapy Active, not recruiting NCT01590992 Phase 2, Phase 3
41 Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles Not yet recruiting NCT03223298 Phase 3 Botulinum toxin type A;0.9% Sodium Chloride Injection
42 Botulinum Toxin Type A for the Treatment of Male Chronic Pelvic Pain Syndrome Terminated NCT00464373 Phase 3 Botulinum Toxin Type A;Placebo
43 Study of Patients With Body Image Issues Treated With 2 Different Behavioral Interventions Unknown status NCT01316627 Phase 2
44 The Use of Zoledronic Acid to Complex Regional Pain Syndrome Unknown status NCT01788176 Phase 2 Zoledronic acid;Placebo
45 Effect of Delta-9-Tetrahydrocannabinol on the Prevention of Chronic Pain in Patients With Acute CRPS (ETIC-Study) Unknown status NCT00377468 Phase 2 Delta9-Tetrahydrocannabinol
46 Rehabilitation of Conversion Gait Disorder Unknown status NCT01422278 Phase 1, Phase 2
47 Cognitive Behavior Therapy for Somatization Disorder Completed NCT00276887 Phase 2
48 Imipramine Treatment for Patients With Multi-organ Bodily Distress Syndrome Completed NCT01518634 Phase 2 Imipramine treatment;Placebo
49 Effectiveness of Cognitive-Affective Behavior Therapy for the Treatment of Somatization Disorder Completed NCT00149760 Phase 2
50 Effects of Emotional Stimulation on the Stress Levels of Healthy Persons Completed NCT01187797 Phase 1, Phase 2

Search NIH Clinical Center for Somatoform Disorder

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Somatoform Disorder

Anatomical Context for Somatoform Disorder

MalaCards organs/tissues related to Somatoform Disorder:

38
Prostate, Brain, Cortex, Testes, Prefrontal Cortex, Spinal Cord, Bone

Publications for Somatoform Disorder

Articles related to Somatoform Disorder:

(show top 50) (show all 104)
# Title Authors Year
1
Somatoform disorder as a predictor of interstitial cystitis/bladder pain syndrome: Evidence from a nested case-control study and a retrospective cohort study. ( 28471951 )
2017
2
Self-compassion in somatoform disorder. ( 29407566 )
2017
3
The CIPRUS study, a nurse-led psychological treatment for patients with undifferentiated somatoform disorder in primary care: study protocol for a randomised controlled trial. ( 28468642 )
2017
4
Harm avoidance and persistence are associated with somatoform disorder psychopathology: A study in Taiwan. ( 26919056 )
2016
5
Suicidality in patients with somatoform disorder - the speechless expression of anger? ( 27821358 )
2016
6
Somatic symptom disorder and undifferentiated somatoform disorder, which is broader? Response to "Clinical value of DSM IV and DSM 5 criteria for diagnosing the most prevalent somatoform disorders in patients with medically unexplained physical symptoms (MUPS)". ( 27542553 )
2016
7
Cognitive Alexithymia Mediates the Association Between Avoidant Attachment and Interpersonal Problems in Patients With Somatoform Disorder. ( 27185015 )
2016
8
Dysaesthetic penoscrotodynia may be a somatoform disorder: results from a two-centre retrospective case series. ( 26932754 )
2016
9
Depression and anxiety among patients with somatoform disorders, panic disorder, and other depressive/anxiety disorders in Taiwan. ( 27179181 )
2016
10
The Relationship of Hypochondriasis to Anxiety, Depressive, and Somatoform Disorders. ( 26785798 )
2016
11
Intensive multidisciplinary treatment of severe somatoform disorder: a prospective evaluation. ( 25594786 )
2015
12
Insecure attachment strategies are associated with cognitive alexithymia in patients with severe somatoform disorder. ( 26060261 )
2015
13
The day-to-day concurrence of bodily complaints and affect in patients with severe somatoform disorder. ( 26032264 )
2015
14
A sudden onset of a pseudo-neurological syndrome after HPV-16/18 AS04-adjuvated vaccine: might it be an autoimmune/inflammatory syndrome induced by adjuvants (ASIA) presenting as a somatoform disorder? ( 25388965 )
2014
15
Relationship between alexithymia and coping strategies in patients with somatoform disorder. ( 24403835 )
2014
16
The spiral aftereffect technique (SAT) can differentiate between depressive and somatoform disorder patients. ( 24897884 )
2014
17
Effectiveness of psychotherapy for severe somatoform disorder: meta-analysis. ( 24385460 )
2014
18
Is the DSM-5 chapter on somatic symptom disorder any better than DSM-IV somatoform disorder? ( 25029686 )
2014
19
Effect of aripiprazole augmentation for treatment-resistant somatoform disorder: a case series. ( 24525655 )
2014
20
Fibromyalgia syndrome: a somatoform disorder? ( 24453056 )
2014
21
Psychotherapy for severe somatoform disorder: problems with missing studies. ( 24590981 )
2014
22
Somatoform disorders in patients with chronic pain. ( 24288382 )
2013
23
Cognitive and affective dimensions of difficulties in emotional functioning in somatoform disorders and borderline personality disorder. ( 23006331 )
2013
24
Explanatory models of somatoform disorder patients attending a psychiatry outpatient clinic: A study from North India. ( 24029246 )
2013
25
Changes in brain activity of somatoform disorder patients during emotional empathy after multimodal psychodynamic psychotherapy. ( 23966922 )
2013
26
Hypochondriasis, somatoform disorders, and anxiety disorders: sociodemographic variables, general psychopathology, and naturalistic treatment effects. ( 22551794 )
2012
27
Definition and structure of body-relatedness from the perspective of patients with severe somatoform disorder and their therapists. ( 22905144 )
2012
28
Dysfunctional affect regulation in borderline personality disorder and in somatoform disorder. ( 22984638 )
2012
29
Somatoform disorder and the DSM-V Workgroup's interim proposals: two central issues. ( 22664310 )
2012
30
Combination of citalopram plus paliperidone is better than citalopram alone in the treatment of somatoform disorder: results of a 6-week randomized study. ( 22367417 )
2012
31
Relationship between neural activity and immunity in patients with undifferentiated somatoform disorder. ( 22801462 )
2012
32
Effect of tryptophan hydroxylase gene polymorphism on aggression in major depressive disorder and undifferentiated somatoform disorder. ( 22697203 )
2012
33
Prevalence, demographic and clinical characteristics of body dysmorphic disorder among psychiatric outpatients with mood, anxiety or somatoform disorders. ( 22029732 )
2012
34
Presentation of the Multidisciplinary Guideline Medically Unexplained Physical Symptoms (MUPS) and Somatoform Disorder in the Netherlands: disease management according to risk profiles. ( 22281461 )
2012
35
Validation of the PHQ-15 for somatoform disorder in the occupational health care setting. ( 21785907 )
2012
36
Rethinking the Psychogenic Model of Complex Regional Pain Syndrome: Somatoform Disorders and Complex Regional Pain Syndrome. ( 24223338 )
2012
37
Public familiarity with the terms somatoform disorder and functional disorder in Germany: results from a representative population survey. ( 22690365 )
2012
38
Altered brain activity during emotional empathy in somatoform disorder. ( 21998038 )
2012
39
Gabapentin as add-on treatment for somatoform disorder: a case report. ( 22240859 )
2012
40
Course and prediction of somatoform disorder and medically unexplained symptoms in primary care. ( 21762827 )
2011
41
A suspected case of somatoform disorder successfully treated with an herbal medicine. ( 21299430 )
2011
42
Childhood traumatization by primary caretaker and affect dysregulation in patients with borderline personality disorder and somatoform disorder. ( 22893813 )
2011
43
Serotonin-related gene pathways associated with undifferentiated somatoform disorder. ( 21531467 )
2011
44
Somatoform disorder after conscious sedation. ( 22136794 )
2011
45
Multimodal psychodynamic psychotherapy induces normalization of reward related activity in somatoform disorder. ( 21198419 )
2011
46
Association of somatoform disorder symptoms with genetic variants potentially involved in the modulation of nociception. ( 21037510 )
2011
47
Shared neural activity in panic disorder and undifferentiated somatoform disorder compared with healthy controls. ( 20673555 )
2010
48
Acoustic neuroma identified after electroconvulsive therapy in a patient with recurrent major depression and undifferentiated somatoform disorder. ( 20357670 )
2010
49
The concept of comorbidity in somatoform disorder--a DSM-V alternative for the DSM-IV classification of somatoform disorder. ( 20004307 )
2010
50
Affect dysregulation and dissociation in borderline personality disorder and somatoform disorder: differentiating inhibitory and excitatory experiencing states. ( 20938867 )
2010

Variations for Somatoform Disorder

Expression for Somatoform Disorder

Search GEO for disease gene expression data for Somatoform Disorder.

Pathways for Somatoform Disorder

Pathways related to Somatoform Disorder according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.39 IL1A IL1B IL2RA IL4
2 12.33 COMT NGF OPRM1 SCN9A TPH1
3 12.28 CABIN1 IL1B IL1RN IL2RA IL4
4
Show member pathways
12.21 IL1A IL1B IL4 OPRM1
5
Show member pathways
11.95 IL1A IL1B IL4
6
Show member pathways
11.83 IL1A IL1B IL2RA
7 11.79 IL1A IL1B IL4
8
Show member pathways
11.75 IL1B IL2RA IL4
9 11.61 IL1A IL1B IL4 OPRM1
10 11.56 IL1B IL2RA IL4
11
Show member pathways
11.51 CABIN1 IL2RA IL4
12 11.44 IL1A IL1B IL2RA IL4
13 11.31 IL1A IL1B IL1RN NGF TAC1 TPH1
14 10.97 IL1A IL1B IL4
15 10.95 IL1A IL1B IL1RN IL4
16 10.59 IL1B IL4
17 10.28 IL1A IL1B

GO Terms for Somatoform Disorder

Biological processes related to Somatoform Disorder according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.89 IL1A IL1B IL1RN IL2RA IL4
2 regulation of receptor activity GO:0010469 9.88 IL1A IL1B IL1RN IL4 NGF
3 cell surface receptor signaling pathway GO:0007166 9.84 CABIN1 IL2RA TRPA1 TRPV1
4 inflammatory response GO:0006954 9.8 IL1A IL1B IL1RN IL2RA SCN9A TAC1
5 response to lipopolysaccharide GO:0032496 9.72 COMT GCH1 IL1B OPRM1 TAC1
6 positive regulation of T cell proliferation GO:0042102 9.61 IL1B IL2RA IL4
7 positive regulation of T cell differentiation GO:0045582 9.56 IL2RA IL4
8 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.55 IL1A IL1B
9 sensory perception of pain GO:0019233 9.55 OPRM1 SCN9A TAC1 TRPA1 TRPV1
10 positive regulation of monocyte chemotactic protein-1 production GO:0071639 9.52 IL1A IL1B
11 behavioral response to pain GO:0048266 9.51 SCN9A TRPV1
12 ectopic germ cell programmed cell death GO:0035234 9.46 IL1A IL1B
13 detection of chemical stimulus involved in sensory perception of pain GO:0050968 9.4 TRPA1 TRPV1
14 thermoception GO:0050955 9.37 TRPA1 TRPV1
15 fever generation GO:0001660 9.26 IL1A IL1B IL1RN TRPV1
16 response to pain GO:0048265 9.02 COMT GCH1 TAC1 TRPA1 TRPV1

Molecular functions related to Somatoform Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 IL1A IL1B IL1RN IL4
2 calcium-release channel activity GO:0015278 9.16 TRPA1 TRPV1
3 interleukin-1 receptor binding GO:0005149 8.8 IL1A IL1B IL1RN

Sources for Somatoform Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....